Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.
Chang-Monteagudo A, Ochoa-Azze R, Climent-Ruiz Y, Macías-Abraham C, Rodríguez-Noda L, Valenzuela-Silva C, Sánchez-Ramírez B, Perez-Nicado R, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, García-García MLÁ, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Rodríguez-Prieto LD, Puga-Gómez R, Guerra-Chaviano PP, Zúñiga-Rosales Y, Marcheco-Teruel B, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Porto-González D, Fernández-Medina O, Valdés-Zayas A, Chen GW, Herrera-Martínez L, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Chang-Monteagudo A, et al. Lancet Reg Health Am. 2021 Dec;4:100079. doi: 10.1016/j.lana.2021.100079. Epub 2021 Sep 15. Lancet Reg Health Am. 2021. PMID: 34541571 Free PMC article.
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Ángeles García-García M, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, Calcagno A, Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Ochoa-Azze R, et al. Among authors: chang monteagudo a. Lancet Respir Med. 2022 Aug;10(8):785-795. doi: 10.1016/S2213-2600(22)00100-X. Epub 2022 Jun 9. Lancet Respir Med. 2022. PMID: 35691295 Free PMC article. Clinical Trial.
Molecular study of a large cohort of 109 haemophilia patients from Cuba using a gene panel with next generation sequencing-based technology.
Borràs N, Castillo-González D, Comes N, Martin-Fernandez L, Rivero-Jiménez RA, Chang-Monteagudo A, Ruiz-Moleón V, Garrote-Santana H, Vidal F, Macías-Abraham C. Borràs N, et al. Among authors: chang monteagudo a. Haemophilia. 2022 Jan;28(1):125-137. doi: 10.1111/hae.14438. Epub 2021 Oct 28. Haemophilia. 2022. PMID: 34708896
Biomarkers of sequela in adult patients convalescing from COVID-19.
Marsán-Suárez V, Casado-Hernández I, Hernández-Ramos E, Díaz-Domínguez G, Triana-Marrero Y, Duarte-Pérez Y, Miranda-Navarro J, Bringas-Pérez R, Simón-Pita AM, Hernández-Rego YLM, Miguel-Morales M, Patria-Sánchez M, Zamora-González Y, Romero-Díaz Y, Aquino-Rojas S, González-Díaz I, Merlín-Linares JC, Leyva-Rodríguez A, Rodríguez-Pérez M, Benito-Caballero O, Navarro-Mariño JA, Elejalde-Larrinaga AR, Elejalde-Tamayo C, Tam-Rey LM, Ruiz-Villegas L, de la Guardia-Peña OM, Jerez-Barcel Y, Chang-Monteagudo A, Lam-Díaz RM, Macías-Abraham CM. Marsán-Suárez V, et al. Among authors: chang monteagudo a. Adv Biomark Sci Technol. 2022;4:36-53. doi: 10.1016/j.abst.2022.10.001. Epub 2022 Nov 9. Adv Biomark Sci Technol. 2022. PMID: 36404876 Free PMC article.